Published in Cancer Weekly, June 9th, 1997
The company also announced that it will begin enrolling patients in a U.S. Phase IIb clinical trial of this anti-idiotype induction (AIT) vaccine for the adjuvant treatment of patients with advanced ovarian cancer.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.